drugset / Trial / NCT03058289
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Phase 1/2
Completed
111 enrolled
Intensity Therapeutics, Inc.
Bristol-Myers Squibb · collabMerck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also tested INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.
Timeline
- Start
- 2017-02-09
- Primary completion
- 2023-02-22
- Completion
- 2023-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INT230-6 | Unknown | — | Other |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |